HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on August 11, 2022 at 4:30 p.m. Eastern Time to discuss its second quarter results, which ended June 30, 2022. The call will also cover recent announcements and key milestones for 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will present and facilitate a Q&A session. Investors can access the call via dial-in or webcast. A replay will be available after the call until November 11, 2022.
HeartBeam, Inc. (NASDAQ: BEAT) announced an expansion of its clinical validation study to include a broader patient population for its emergency department software technology. The decision follows the recent AHA guidelines and aims to include unstable angina patients, which may enhance heart attack detection. HeartBeam plans to file a 510K submission by August 15, 2022, which remains unaffected by the Telehealth product's timeline, scheduled for Q4 2022. This expanded scope aligns with their goal of improving cardiovascular diagnosis.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare innovator, will present at the LD Micro Invitational XII Conference from June 7-9, 2022, in Westlake Village, CA. CFO Rick Brounstein and CBO Jon Hunt, PhD, will host 25-minute meetings and deliver a presentation on June 7 at 4:00 pm ET. HeartBeam specializes in proprietary ECG telemedicine technology aimed at improving heart attack detection outside medical institutions. This significant advancement addresses the high-risk cardiovascular patient population's needs. For more details, visit ir.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) will participate virtually in the H.C. Wainwright Global Investment Conference from May 23 – 26, 2022.
The company's CEO, Branislav Vajdic, CFO Rick Brounstein, and CBO Jon Hunt will conduct one-on-one meetings during the event. Jon Hunt will also deliver a virtual presentation available on-demand starting May 24, 2022.
This innovative digital healthcare company focuses on ECG telemedicine technology for heart attack detection, providing significant advancements in diagnosing cardiovascular diseases outside medical institutions.
HeartBeam, a digital healthcare company (NASDAQ: BEAT), reported its Q1 2022 results, highlighting a net loss of $2.1 million, up from $210,000 in Q1 2021. R&D expenses increased significantly to $734,000, compared to $29,000 in the prior year. The company remains on track for an FDA submission for its Emergency Department Myocardial Infarction software in Q2 2022 and a Telehealth solution in Q4 2022. With cash reserves of $11.2 million, HeartBeam anticipates a full commercial rollout of its ED Software Tool in Q1 2023.
The acquisition of RedCrow by Alira Health aims to enhance access to alternative investments in healthcare startups. Founded in 2016, RedCrow has raised $250 million through over 250 fundraises. This strategic move allows Alira to extend its patient engagement mission by involving them in the financing of new healthcare solutions. The financial terms of the acquisition remain undisclosed, but the collaboration is expected to democratize healthcare investing, promoting innovation in early-stage pharma and MedTech.
HeartBeam, Inc. (NASDAQ: BEAT) announces a conference call on May 12, 2022 at 4:30 p.m. Eastern time, to discuss its first-quarter results for the period ending March 31, 2022. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. Participants can join via telephone or webcast. A replay will be available until July 12, 2022. HeartBeam specializes in digital healthcare technology for heart attack detection using an innovative ECG device. For further details, visit www.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.
HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.